Melanotan II: Cyclic Lactam Design, Melanocortin Receptor Pharmacology, and the Analytical Problem — A 2026 Research Guide

Melanotan II occupies an unusual position in peptide science. It is simultaneously one of the most carefully engineered molecules in the melanocortin field — a deliberate exercise in conformational constraint that came out of computational design work at the University of Arizona in the late 1980s — and one of the most poorly characterized compounds circulating in the gray market, where published analytical surveys have repeatedly found material at a fraction of its labeled content. The gap between those two facts is the reason a sourcing conversation about this compound has to start with the certificate of analysis rather than the price. Melanotan II is also on the FDA’s near-term regulatory calendar: it is one of five bulk substances scheduled for Pharmacy Compounding Advisory Committee review in February 2027. This guide covers the molecular profile, the receptor-level mechanism, the published preclinical record, and what the analytical data on this particular molecule actually needs to show.

The information below describes in-vitro and preclinical laboratory research only. It is not medical guidance, and none of the findings described here establish safety or efficacy in humans.

Section 1 — Molecular Profile

Melanotan II is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). It is a truncated, conformationally constrained version of the α-MSH core message sequence, closed by a lactam bridge between an aspartic acid side chain and a lysine side chain.

Key identifiers used in the literature and on analytical documentation:

• Compound name: Melanotan II; MT-II; MT-2; melanotan-2
• CAS number: 121062-08-6 (free base); commonly supplied as the acetate salt
• Molecular formula: C50H69N15O9
• Molecular weight: approximately 1,024.2 Da
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
• Structure class: cyclic lactam heptapeptide; non-selective melanocortin receptor agonist
• Modifications: N-terminal acetylation, C-terminal amidation, side-chain-to-side-chain lactam cyclization (Asp→Lys), norleucine substitution at the Met position, and a D-phenylalanine inversion at position 7

Four structural interventions are stacked into a seven-residue chain, each with a specific purpose. The methionine of native α-MSH is replaced with norleucine to remove an oxidation-labile side chain. The L-phenylalanine at position 7 is inverted to D-phenylalanine — the modification that produced the “superpotent” linear analog NDP-α-MSH and that stabilizes the bioactive β-turn. The termini are capped to block exopeptidase attack. And the lactam bridge between Asp5 and Lys10 locks the backbone into the turn geometry the receptors recognize, reducing the conformational entropy the peptide pays on binding.

That last point is the design thesis. Al-Obeidi, Hadley, Pettitt, and Hruby published the cyclization strategy in 1989 in two companion papers — one in the Journal of the American Chemical Society, one in the Journal of Medicinal Chemistry — describing a new class of cyclic melanotropins designed from quenched molecular dynamics simulations rather than from empirical structure–activity iteration. The simulations identified a preferred turn conformation in the message sequence; the lactam bridge was placed to enforce it.

Handling consequences follow from the composition. At 1,024 Da the molecule is small and well behaved by peptide standards, water-soluble, and considerably more stable than the linear parent. The two basic residues (Arg, Lys) mean lyophilized material carries a counterion load, typically acetate or trifluoroacetate depending on purification route, so gross vial weight and net peptide content are not the same figure. Standard practice is storage at −20°C or below, desiccated and protected from light, with reconstituted stock aliquoted to avoid freeze-thaw cycling. The tryptophan residue makes the molecule photolabile in solution — a routine but real source of drift in long assays.

Section 2 — Mechanism

All activity described here is at the receptor and pathway level, in defined experimental systems.

The receptor family. The melanocortin system comprises five G protein-coupled receptors, MC1R through MC5R, all of which signal principally through Gs and adenylyl cyclase to raise intracellular cAMP. They differ in tissue distribution: MC1R on melanocytes and immune cells, MC2R as the ACTH receptor in the adrenal cortex, MC3R and MC4R predominantly in the central nervous system, MC5R in exocrine tissue. MT-II is a non-selective agonist across MC1R, MC3R, MC4R, and MC5R — it does not engage MC2R, which is selective for ACTH. Reported binding affinities place it in the sub-nanomolar to low-nanomolar range across the four receptors it does bind, with MC1R typically the tightest.

Why it binds everything. The His-D-Phe-Arg-Trp tetrapeptide inside the lactam ring is the conserved “message” sequence common to α-MSH, ACTH, and the other melanocortins, and it is the segment all five receptors evolved to recognize. Constraining that sequence into its bioactive conformation raises affinity everywhere at once. Selectivity in the melanocortin field has historically come from modifications outside the message — which is precisely what the subsequent literature did, and why MT-II became a scaffold rather than an endpoint.

MC1R and the melanogenesis cascade. The best-characterized in-vitro pathway is the melanocyte one. MC1R activation raises cAMP, cAMP activates protein kinase A, PKA phosphorylates CREB, and CREB drives transcription of MITF — the master regulator of the pigmentation program. MITF in turn drives expression of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), dopachrome tautomerase (DCT), and PMEL. Tyrosinase is the rate-limiting enzyme of melanin synthesis, so tyrosinase activity in cultured melanocytes is the standard functional readout for MC1R agonism. This cascade is measurable in cell culture and is what “melanogenesis” means in an in-vitro context: transcript and enzyme-activity changes in a dish, not any organismal outcome.

MC3R/MC4R and central signaling. MC3R and MC4R are CNS receptors studied extensively in preclinical neuroscience and receptor-pharmacology work. MT-II’s utility there has been as a non-selective pharmacological probe — the agonist you use to activate the system broadly, then dissect with receptor-subtype knockouts or with selective antagonists such as SHU-9119. A great deal of what is known about which melanocortin receptor mediates which signal in rodent models was established by pairing MT-II with a subtype-specific tool.

MC5R. MC5R is the least-studied subtype; MT-II’s activity at it is the reason later medicinal chemistry campaigns spent so much effort trying to remove MC5R activity from the scaffold.

Throughout the literature these are mechanisms MT-II has been studied for and researched for — melanocortin receptor agonism, cAMP/PKA/CREB/MITF pathway activation in melanocyte culture, and use as a non-selective probe in preclinical receptor-dissection experiments — not demonstrated clinical effects in humans.

Section 3 — Preclinical and In-Vitro Research Data

The MT-II record is overwhelmingly a medicinal-chemistry record. The compound’s largest contribution to the field is as a scaffold: dozens of published analog series begin with MT-II and modify one position at a time to see what selectivity emerges.

Selectivity engineering from the MT-II scaffold. Bednarek and colleagues at Merck published a sustained effort on this. Their 1999 Biochemical and Biophysical Research Communications paper reported that replacing the Nle4 residue with proline yielded [Pro4]MT-II, which retained MT-II-like affinity and agonist potency at hMC4R while losing roughly 400-fold potency at hMC5R and about 20-fold at hMC3R — a large selectivity gain from a single substitution outside the message sequence. That result prompted a series of further N-terminally modified analogs, and a 2007 follow-up in Peptides extended the same structure–activity mapping across lactam derivatives of both MT-II and the antagonist SHU-9119 at hMC3R, hMC4R, and hMC5R.

Backbone N-methylation and hMC1R selectivity. A 2010 study in the Journal of the American Chemical Society by Doedens and colleagues took a different route to the same goal: systematic N-methylation of the MT-II backbone amide bonds. Multiple N-methylation produced analogs with hMC1R selectivity, and the paper paired the pharmacology with NMR conformational analysis showing how each methylation shifted the accessible backbone conformations. It is one of the cleaner demonstrations in the peptide literature that selectivity can be encoded in backbone geometry rather than in side-chain identity.

Conformational and structural work. NMR and quenched molecular dynamics studies of superpotent linear and cyclic α-melanotropins, published in 1998, characterized the solution conformations of this compound class and supported the turn-constraint rationale behind the original design. Later work continued to probe systematic backbone conformational constraints on the cyclic melanotropin scaffold to generate subtype-selective ligands.

Preclinical rodent pharmacology. MT-II appears widely in rodent studies as the non-selective agonist arm of receptor-dissection experiments. As one representative example, work published in Alcoholism: Clinical and Experimental Research and related journals used MT-II in MC3R-knockout mice to determine which receptor subtype mediated an observed central melanocortin effect — the knockout, not the peptide, being the informative variable. Melanocortin analogs have also been examined in preclinical bone and immune models. Across this body of work MT-II functions as a reagent.

The bremelanotide lineage. MT-II’s most consequential downstream product is PT-141 (bremelanotide), which is the C-terminal carboxylic acid analog of MT-II — a single terminal modification away. Hadley and Dorr’s 2006 review in Peptides documents the historical arc from the University of Arizona melanotropin program through the analogs that followed. For researchers, the relevant point is structural: MT-II and PT-141 are close enough that identity confirmation by mass is not optional, since the two differ by roughly one dalton in a way that a careless analytical method can miss.

Two limitations should be stated plainly. First, this is a preclinical and in-vitro record; nothing in it establishes human safety or efficacy, and the compound has no approved status in any jurisdiction. Second, published reviews of chronic melanocortin-1 receptor activation — including a 2024 overview in the British Journal of Pharmacology — note that the long-term consequences of sustained MC1R agonism remain incompletely characterized even at the preclinical level. That is an open scientific question, not a settled one.

Section 4 — Published Literature

The following are real, published papers anchoring the MT-II record. Researchers should consult the primary sources rather than relying on summaries.

• Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ (1989). “Design of a New Class of Superpotent Cyclic α-Melanotropins Based on Quenched Dynamic Simulations.” Journal of the American Chemical Society 111(9):3413–3416. The originating design paper.
• Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ (1989). “Potent and prolonged acting cyclic lactam analogues of α-melanotropin: design based on molecular dynamics.” Journal of Medicinal Chemistry 32(12):2555–2561.
• Bednarek MA, MacNeil T, Kalyani RN, et al. (1999). “Analogs of MTII, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5.” Biochemical and Biophysical Research Communications 261(1):209–213. PMID 10405347.
• Bednarek MA, et al. (2007). “Further structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5.” Peptides. PMID 17482720.
• Doedens L, Opperer F, Cai M, et al. (2010). “Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.” Journal of the American Chemical Society 132(23):8115–8128. PMC2895553.
• NMR and quenched molecular dynamics studies of superpotent linear and cyclic α-melanotropins (1998). PMID 9650716.
• Hadley ME, Dorr RT (2006). “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides 27(4):921–930.
• Hruby VJ, Cai M, Cain J, et al. (2011). “Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challenge.” European Journal of Pharmacology. PMID 21208601.
• Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects (2023). International Journal of Molecular Sciences. PMC10418475. Current MC1R pharmacology review.
• An overview of benefits and risks of chronic melanocortin-1 receptor activation (2024). British Journal of Pharmacology. PMC11664455.
• Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet (2014). PMID 24771717. Analytical survey of unregulated material.
• LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs (2020). PMID 33245851.
• Barbie drug identification: Not a child’s play (2024). PMID 39302005. Forensic identification of seized MT-II material.

Together these span the computational design origin, three decades of selectivity engineering, the conformational structural work, current receptor pharmacology reviews, and — unusually for a research peptide — a genuine forensic-analytical literature on what unregulated material actually contains.

Section 5 — Research Applications

In laboratory settings, MT-II appears principally as a reference melanocortin agonist. Reported in-vitro applications include use as the non-selective positive control in MC1R–MC5R receptor binding and cAMP accumulation assays in transfected CHO or HEK cell lines; as the agonist arm in tyrosinase-activity and MITF/TYR/TYRP1 expression assays in cultured melanocytes and B16 murine melanoma cells; as the parent scaffold in structure–activity series exploring subtype selectivity; as the comparator against which selective agonists and the antagonist SHU-9119 are benchmarked; and as a conformational reference in NMR and molecular-dynamics studies of constrained peptide backbones.

Assay-design variables worth attention. Melanocortin receptor expression level strongly influences apparent potency in cAMP assays, so EC50 values are not directly comparable across cell lines without stating receptor density. The tryptophan residue makes the peptide photolabile in solution — amber vials and light-protected plates are standard for extended incubations. Adsorptive loss is modest relative to highly cationic peptides but non-zero at low working concentrations, and low-binding labware remains sensible below the micromolar range. And because MC1R signaling converges on cAMP, any assay run in the presence of phosphodiesterase inhibitors will report a different dynamic range than one run without them; the condition needs to be reported, not assumed.

Section 6 — How to Evaluate a Source

Melanotan II is one of the few research peptides where the quality question has been answered empirically in the peer-reviewed literature, and the answer is not reassuring.

A 2014 LC-UV-MS/MS study of MT-II products sold over the internet found vials containing between 4.32 and 8.84 mg of peptide against a labeled content of 10 mg, with unidentified impurities of 4.1% to 5.9% in material from two of the three sources examined. Subsequent LC-HRMS work on seized black-market material, and a 2024 forensic identification study, reported comparable findings — including at least one sample assaying near 30% purity. These are published measurements, not vendor claims. They mean that for this specific compound, an unverified purity figure has a documented history of being wrong by a factor that would invalidate any dose-response curve built on it.

What the analytical package needs to show:

• Purity by HPLC, with a stated percentage and the chromatogram. On a cyclic peptide, the dominant impurity classes are the linear (uncyclized) precursor and cyclodimer species. The linear precursor is not a trace contaminant of no consequence — it is a different pharmacological entity with different receptor behavior, and it elutes close enough to matter. A bare “≥99%” without a trace tells you nothing about which 1% is present.
• Identity by LC-MS, with an observed mass consistent with approximately 1,024.2 Da for the free base. Two specific checks belong here: the ~18 Da difference that distinguishes cyclic MT-II from its uncyclized linear form, and the roughly 1 Da difference between MT-II (C-terminal amide) and bremelanotide/PT-141 (C-terminal acid). A method with insufficient resolution to separate those is not an identity confirmation.
• Endotoxin by USP <85> LAL, with an actual figure rather than a “meets specification” checkbox.
• Heavy metals by ICP-MS.
• Net peptide content and counterion, disclosed. Acetate and trifluoroacetate salts carry meaningfully different mass burdens, and TFA itself is biologically active in some cell assays at concentrations that survive lyophilization.
• Lot-specificity. The COA must correspond to the exact batch shipped, be dated, and name the accredited laboratory that performed the testing. A generic COA reused across lots is a marketing document.

Market pricing context: research-grade MT-II at the 10 mg scale is widely listed in the roughly $12–$25 range at the low end of the market and roughly $25–$50 at vendors claiming independent testing, with bulk pricing below both. Synthesis economics for a capped, cyclized heptapeptide are genuinely favorable — this is not an expensive molecule to make correctly — which is exactly why price tells you so little here. The 2014 and 2020 analytical studies found underfilled, impure vials at every price point they sampled. The differentiator is not cost; it is whether a named accredited laboratory tested the specific lot in your hand and published the chromatogram.

Regulatory note: on 15 April 2026 the FDA announced the removal of twelve peptide bulk substances from Category 2 and scheduled Pharmacy Compounding Advisory Committee meetings to consider adding peptides to the 503A bulk drug substances list. The July 2026 PCAC meeting addressed the first seven. Melanotan II is among the five substances — alongside LL-37, GHK-Cu, dihexa acetate, and PEG-MGF — scheduled for the committee’s next session, expected in February 2027. A PCAC vote is advisory: FDA must still complete notice-and-comment rulemaking before anything is added to the list, and nothing about that process changes the research-use-only status of material supplied for laboratory work.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

On a compound with this particular published history, that is not a marketing posture. It is the only thing that separates a usable experimental input from a number on a label.

Founding batches are documented end to end, and full analytical data files are available per lot. You can review current documentation in the COA library, read the underlying methodology on the verification standard page, or browse the full catalog in the shop.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.